The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy

BJU International

Volumn 99, Issue 5, 2007, Pages 1150-1153

  Peyromaure, Michaël ^a   Camparo, Philippe ^b   Badoual, Cécile ^c   Descazeaud, Aurélien ^a   Dinh Xuan, Anh Tuan ^a  

^a Institut Cochin   (France)

^b University of Paris Descartes   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Angiogenesis; Prostate cancer; Radical prostatectomy; Vascular endothelial growth factor

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE INTERVAL; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MALE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; TISSUE MICROARRAY; TREATMENT OUTCOME;

AGED; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247174730     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06734.x     Document Type: Article

References (17)

1. Delongchamps NB, Peyromaure M, Dinh-Xuan AT. Role of vascular endothelial growth factor in prostate cancer. Urology 2006; 68: 244-8
2. Kwak C, Jin RJ, Lee C, Park MS, Lee SE. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 2002; 89: 303-9
3. Jones A, Fujiyama C, Turner K et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 2000; 85: 276-80
4. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54: 523-7
5. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004; 22: 1655-63
6. Li R, Younes M, Wheeler TM et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004; 58: 193-9
7. Jennbacken K, Vallbo C, Wang W, Damber JE. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005; 65: 110-6
8. Trojan L, Rensch F, Voss M et al. The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer. BJU Int 2006; 98: 903-6
9. Strohmeyer D, Rossing C, Bauerfeind A et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000; 45: 216-24
10. West AF, O'Donnell M, Charlton RG, Neal DE, Leung HY. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 2001; 85: 576-83
11. Haukaas SA, Halvorsen OJ, Daehlin L, Hostmark J, Akslen LA. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? BJU Int 2006; 97: 51-5
12. Yokomizo A, Murai M, Baba S et al. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU Int 2006; 98: 549-53
13. Bott SR, Freeman AA, Stenning S, Cohen J, Parkinson MC. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. BJU Int 2005; 95: 34-9
14. Khan MA, Partin AW. Surgical margin status after radical retropubic prostatectomy. BJU Int 2005; 95: 281-4
15. Brooks JP, Albert PS, Wilder RB, Gant DA, McLeod DG, Poggi MM. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. J Urol 2005; 174: 2204-8
16. Swanson GP, Riggs MW, Earle JD, Haddock MG. Long-term follow-up of radical retropubic prostatectomy for prostate cancer. Eur Urol 2002; 42: 212-6
17. Picus J, Halabi S, Rini B. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003; 22: 393 (Abstract 1578)